Phase 3 trial of secukinumab in polymyalgia rheumatica (Registro nro. 22824)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03417nam a2200361 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260817155615.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | spa |
| 100 ## - Autor | |
| Autor | Stone, John H. |
| Rol del Autor | Autor |
| 9 (RLIN) | 54096 |
| 245 ## - Titulo | |
| Titulo | Phase 3 trial of secukinumab in polymyalgia rheumatica |
| 300 ## - Páginas | |
| Paginación | páginas: 637-647 |
| 520 ## - Resumen | |
| Resumen | Background: Polymyalgia rheumatica is a common inflammatory disease characterized by pain and stiffness in the shoulders and hips. Glucocorticoids are the first-line treatment, but relapses and glucocorticoid-related toxic effects are common, which underscores the need for effective alternatives. Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A. Methods: We enrolled patients with recently relapsed polymyalgia rheumatica and randomly assigned them, in a 1:1:1 ratio, to receive secukinumab at a dose of 300 mg (SEC-300 group), secukinumab at a dose of 150 mg (SEC-150 group), or placebo for 52 weeks. Patients in all the groups also received prednisone on a tapering schedule for 24 weeks. The primary outcome was sustained remission at week 52, defined as remission (the absence of signs or symptoms attributable to polymyalgia rheumatica and no new diagnosis of giant-cell arteritis that warranted escape or rescue treatment) that was sustained from week 12 until week 52. The annual cumulative glucocorticoid dose was a secondary outcome. Safety was also assessed. Results: A total of 381 patients underwent randomization, and 127 were assigned to each group. At 52 weeks, sustained remission was observed in 41.2% (95% confidence interval [CI], 32.8 to 49.7) of the patients in the SEC-300 group, in 40.6% (95% CI, 32.2 to 49.0) of those in the SEC-150 group, and in 20.4% (95% CI, 13.6 to 27.2) of those in the placebo group (P<0.001 for the comparison of each secukinumab dose with placebo). The mean adjusted annual cumulative glucocorticoid dose was 1603.7 mg in the SEC-300 group, 1683.2 mg in the SEC-150 group, and 2093.0 mg in the placebo group. Serious adverse events occurred in 13.5% of the patients in the SEC-300 group, in 15.9% in the SEC-150 group, and in 14.2% in the placebo group. Nasopharyngitis, hypersensitivity reactions, urinary tract infections, fungal infections, and back pain were more common in the secukinumab groups than in the placebo group. Conclusions: Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission and in lower cumulative glucocorticoid doses than a glucocorticoid taper alone. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ALERGIA |
| 9 (RLIN) | 7055 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | INMUNOLOGÍA |
| 9 (RLIN) | 34121 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ENFERMEDAD AUTOINMUNE |
| 9 (RLIN) | 53665 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | MEDICINA CLÍNICA |
| 9 (RLIN) | 33681 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | GERIATRÍA |
| 9 (RLIN) | 1852 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | REUMATOLOGÍA |
| 9 (RLIN) | 7490 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CÉLULAS T |
| 9 (RLIN) | 54097 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | VASCULITIS |
| 9 (RLIN) | 32232 |
| 700 ## - Autor Personal | |
| Autor Personal | Buttgereit, Frank |
| 9 (RLIN) | 54098 |
| 700 ## - Autor Personal | |
| Autor Personal | Saraux, Alain |
| 9 (RLIN) | 54099 |
| 700 ## - Autor Personal | |
| Autor Personal | Schmidt, Wolfgang A. |
| 9 (RLIN) | 54100 |
| 700 ## - Autor Personal | |
| Autor Personal | Dejaco, Christian |
| 9 (RLIN) | 54101 |
| 700 ## - Autor Personal | |
| Autor Personal | Spiera, Robert |
| 9 (RLIN) | 54102 |
| 700 ## - Autor Personal | |
| Autor Personal | Dasgupta, Bhaskar |
| 9 (RLIN) | 54103 |
| 700 ## - Autor Personal | |
| Autor Personal | Drescher, Edit |
| 9 (RLIN) | 54104 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22647 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM010 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-08-17 |
| Catalogador | SQB |
No hay ítems disponibles.